NASDAQ:OBLN - Obalon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.97 +0.02 (+1.03 %)
(As of 10/21/2018 04:00 PM ET)
Previous Close$1.97
Today's Range$1.80 - $2.1329
52-Week Range$1.46 - $9.91
Volume19,725 shs
Average Volume64,318 shs
Market Capitalization$45.87 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.21
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBLN
CUSIPN/A
Phone760-795-6558

Debt

Debt-to-Equity Ratio0.37
Current Ratio2.98
Quick Ratio2.80

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.91 million
Price / Sales4.63
Cash FlowN/A
Price / CashN/A
Book Value$1.54 per share
Price / Book1.28

Profitability

EPS (Most Recent Fiscal Year)($2.08)
Net Income$-34,760,000.00
Net Margins-205.20%
Return on Equity-72.76%
Return on Assets-46.80%

Miscellaneous

Employees113
Outstanding Shares23,280,000
Market Cap$45.87 million

Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) issued its quarterly earnings data on Thursday, August, 2nd. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.06. The firm had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.40 million. Obalon Therapeutics had a negative return on equity of 72.76% and a negative net margin of 205.20%. View Obalon Therapeutics' Earnings History.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, November 2nd 2018. View Earnings Estimates for Obalon Therapeutics.

What price target have analysts set for OBLN?

6 equities research analysts have issued 12-month price objectives for Obalon Therapeutics' shares. Their predictions range from $2.50 to $16.00. On average, they expect Obalon Therapeutics' share price to reach $6.9167 in the next year. This suggests a possible upside of 251.1% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.

What is the consensus analysts' recommendation for Obalon Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obalon Therapeutics.

What are Wall Street analysts saying about Obalon Therapeutics stock?

Here are some recent quotes from research analysts about Obalon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (10/10/2018)
  • 2. Northland Securities analysts commented, "We are tweaking our PT to $2.50, but maintain our Neutral stance." (9/12/2018)
  • 3. BTIG Research analysts commented, "2Q18 results came in light. Though reordering trends were strong in the quarter (+220% sequentially), new accounts sold came in below our expectations. As the company remains in the early innings of its commercial ramp, it appears this quarter that there continues to be refinement of the sales pitch and go-to-market strategy. Going forward, much of the sales focus will be on more productive accounts with OBLN establishing new clinical programs to assist with imaging acquisition – the biggest barrier to initial uptake. We trim our FY18 revenue estimates once again as we think it will take more time for some of these initiatives to bear fruit. In thinking about shares, we think the upcoming investor call (perhaps early September) to more explicitly discuss the marketing strategy and/or PMA approval of the Navigator system in 1H19 may lift sentiment." (8/5/2018)

Who are some of Obalon Therapeutics' key competitors?

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the folowing people:
  • Mr. Andrew P. Rasdal, CEO & Director (Age 60)
  • Dr. Kelly Huang, Pres & COO (Age 49)
  • Mr. Mark C. Brister, Chief Technology Officer (Age 56)
  • Mr. William John Plovanic CFA, CFO & Sec. (Age 49)
  • Mr. Todd Michael Wood, VP of Global Sales

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Who are Obalon Therapeutics' major shareholders?

Obalon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Interwest Venture Management Co. (15.26%). Company insiders that own Obalon Therapeutics stock include Kim P Kamdar, Neil Drake, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

Which major investors are buying Obalon Therapeutics stock?

OBLN stock was acquired by a variety of institutional investors in the last quarter, including Interwest Venture Management Co.. Company insiders that have bought Obalon Therapeutics stock in the last two years include Kim P Kamdar, Neil Drake, Parters Vii L P Domain and William J Plovanic. View Insider Buying and Selling for Obalon Therapeutics.

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $1.97.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $45.87 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.

What is Obalon Therapeutics' official website?

The official website for Obalon Therapeutics is http://www.obalon.com.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]


MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2018 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel